Table 2

Sensitivity and specificity of criteria sets, by duration of symptoms (n %) MSU crystal (a) dependent and (b) independent criteria

Up to 2 yearsOR (95% CI)*More than 2 yearsOR (95% CI)*
(a) Dependent criteria
Sensitivity
 ROME131 (92.9%)5.4 (2.5 to 11.4)350 (99.4%)16.1 (3.8 to 68.6)
 NEW YORK†144 (100.0%)117.8 (7.1 to 1944.4)362 (100.0%)66.8 (4.0 to 1100.6)
 ARA (full)†144 (100.0%)117.8 (7.1 to 1944.4)362 (100.0%)66.8 (4.0 to 1100.6)
 MEX†144 (100.0%)117.8 (7.1 to 1944.4)362 (100.0%)66.8 (4.0 to 1100.6)
Specificity
 ROME171 (86.4%)1.3 (0.7 to 2.0)131 (63.6%)1.7 (1.0 to 2.5)
 NEW YORK199 (87.7%)1.4 (0.8 to 2.5)169 (70.1%)2.0 (1.4 to 3.3)
 ARA (full)107 (85.6%)1.1 (0.6 to 2)67 (47.2%)0.8 (0.5 to 1.3)
 MEX130 (66.3%)0.4 (0.2 to 0.6)70 (34.3%)0.5 (0.3 to 0.7)
(b) Independent criteria
Sensitivity
 ROME (2 of 3 clinical)85 (60.3%)0.62 (0.37 to 1.04)297 (84.4%)0.5 (0.3 to 0.8)
 NEW YORK (2 of 4 clinical)83 (57.6%)0.56 (0.3 to 0.9)315 (87.5%)0.6 (0.4 to 1.07)
 ARA (survey)88 (71.0%)Ref282 (91.6%)Ref
 NETH124 (87.9%)3.0 (1.6 to 5.6)333 (96.0%)2.2 (1.1 to 4.3)
 MEX (clinical)123 (87.2%)2.8 (1.5 to 5.2)342 (98.6%)6.3 (2.4 to 16.6)
Specificity
 ROME (2 of 3 clinical)171 (86.4%)1.3 (0.7 to 2.0)131 (63.6%)1.7 (1.0 to 2.5)
 NEW YORK (2 of 4 clinical)199 (87.7%)1.4 (0.8 to 2.5)169 (70.1%)2.0 (1.4 to 3.3)
 ARA (survey)147 (84.0%)Ref97 (53.0%)Ref
 NETH148 (75.1%)0.6 (0.3 to 1.0)96 (47.1%)0.8 (0.5 to 1.1)
 MEX (clinical)130 (66.3%)0.4 (0.2 to 0.6)70 (34.3%)0.5 (0.3 to 0.7)
  • *ORs for sensitivity represent the odds of each criteria being positive vs being negative in cases compared with the ARA (survey) criteria. ORs for specificity represent the odds of each criteria being negative vs being positive in controls compared with the ARA (survey) criteria. Higher OR means that the criteria are more sensitive (or specific) than the ARA (survey) criteria.

  • †These criteria can be fulfilled with presence of MSU crystals alone.

  • ARA, American Rheumatism Association; MEX, Mexico; MSU, monosodium urate; NETH, Netherlands.